mmmm no. commercially why would you want to offer a drug which is targetting multiple hundreds of thousands of dollar per course for a rare disease for a vaccine side effect treatment (makes it widespread and cheap)? there are plenty of inflammation treatments out there which may do the job and are cheap, ANPs is more specialised and targeted to CD49d. presumably the drug isnt cheap (by comparison) to manufacture either. doesn't make any commercial sense
- Forums
- ASX - By Stock
- PER
- Ann: ANP and MCRI new R&D collaboration for ATL1102
Ann: ANP and MCRI new R&D collaboration for ATL1102, page-274
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
-0.002(2.44%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.3¢ | 8.4¢ | 8.0¢ | $58.49K | 703.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 127624 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 25545 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 127624 | 0.080 |
1 | 3600 | 0.079 |
1 | 10000 | 0.077 |
3 | 86800 | 0.075 |
3 | 180866 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 25545 | 1 |
0.085 | 363000 | 2 |
0.086 | 480000 | 3 |
0.087 | 400000 | 1 |
0.088 | 456000 | 3 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |